Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. [electronic resource]
Producer: 20200707Description: 30-35 p. digitalISSN:- 1532-2742
- Antiviral Agents -- therapeutic use
- Benzimidazoles -- therapeutic use
- Coinfection -- drug therapy
- Female
- Fluorenes -- therapeutic use
- HIV Infections -- complications
- Hepatitis C, Chronic -- drug therapy
- Humans
- Male
- Middle Aged
- Recurrence
- Retrospective Studies
- Sofosbuvir -- therapeutic use
- Sustained Virologic Response
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.